BBIO
NASDAQ · Biotechnology
Bridgebio Pharma Inc
$84.48
+1.68 (+2.03%)
Financial Highlights (FY 2026)
Revenue
515.29M
Net Income
-744,019,304
Gross Margin
95.8%
Profit Margin
-144.4%
Rev Growth
+86.3%
D/E Ratio
8.27
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 95.8% | 95.8% | 62.1% | 62.1% |
| Operating Margin | -108.5% | -97.6% | -18.7% | -16.8% |
| Profit Margin | -144.4% | -137.2% | -18.6% | -18.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 515.29M | 276.59M | 2.34B | 2.57B |
| Gross Profit | 493.75M | 265.03M | 1.46B | 1.60B |
| Operating Income | -558,883,406 | -269,991,983 | -437,527,234 | -431,783,995 |
| Net Income | -744,019,304 | -359,429,615 | -436,239,166 | -483,541,824 |
| Gross Margin | 95.8% | 95.8% | 62.1% | 62.1% |
| Operating Margin | -108.5% | -97.6% | -18.7% | -16.8% |
| Profit Margin | -144.4% | -137.2% | -18.6% | -18.8% |
| Rev Growth | +86.3% | +86.3% | -0.2% | +8.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 7.41B | 7.41B | 6.47B | 5.73B |
| Total Equity | 895.42M | 895.42M | 7.68B | 7.94B |
| D/E Ratio | 8.27 | 8.27 | 0.84 | 0.72 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -553,326,272 | -282,157,787 | -548,703,476 | -540,979,015 |
| Free Cash Flow | — | — | -421,297,535 | -367,960,452 |